Nothing Special   »   [go: up one dir, main page]

MX341243B - Formulacion que comprende una enzima de degradacion de proteoglicano. - Google Patents

Formulacion que comprende una enzima de degradacion de proteoglicano.

Info

Publication number
MX341243B
MX341243B MX2011004013A MX2011004013A MX341243B MX 341243 B MX341243 B MX 341243B MX 2011004013 A MX2011004013 A MX 2011004013A MX 2011004013 A MX2011004013 A MX 2011004013A MX 341243 B MX341243 B MX 341243B
Authority
MX
Mexico
Prior art keywords
chondroitinase
methods
purifying
stable formulations
purifying chondroitinase
Prior art date
Application number
MX2011004013A
Other languages
English (en)
Inventor
O Caggiano Anthony
G Sheptovitsky Yelena
Kasperbauer Sarah
A Gruskin Elliott
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX341243B publication Critical patent/MX341243B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación que comprende una enzima de degradación de proteoglicano seleccionada del grupo que consiste de condroitinasa ABCII, condroitinasa AC, condroitinasa B, o enzimas de mamífero con actividad tipo condroitinasa tal como Hyal 1, Hyal 2, Hyal 3, Hyal 4, y PH20 y el amortiguador fosfato que tiene una concentración de 750 - 1000 Mm, en donde la formulación es estable por al menos 24 horas.
MX2011004013A 2004-05-18 2006-11-17 Formulacion que comprende una enzima de degradacion de proteoglicano. MX341243B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57203004P 2004-05-18 2004-05-18
US62188204P 2004-10-25 2004-10-25

Publications (1)

Publication Number Publication Date
MX341243B true MX341243B (es) 2016-08-12

Family

ID=35428854

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06013345A MXPA06013345A (es) 2004-05-18 2005-05-18 Metodos para purificar condrointinasa y sus formulaciones estables.
MX2011004013A MX341243B (es) 2004-05-18 2006-11-17 Formulacion que comprende una enzima de degradacion de proteoglicano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA06013345A MXPA06013345A (es) 2004-05-18 2005-05-18 Metodos para purificar condrointinasa y sus formulaciones estables.

Country Status (8)

Country Link
US (1) US8226941B2 (es)
EP (1) EP1750757B1 (es)
JP (1) JP4926962B2 (es)
AU (1) AU2005244933B2 (es)
CA (1) CA2566731C (es)
ES (1) ES2411504T3 (es)
MX (2) MXPA06013345A (es)
WO (1) WO2005112986A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
ATE481478T1 (de) 2002-06-03 2010-10-15 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
ES2636653T3 (es) 2003-05-16 2017-10-06 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
ES2642088T3 (es) 2006-10-10 2017-11-15 Acorda Therapeutics, Inc. Composiciones y métodos de uso de mutantes de condroitinasa ABCI
JP2011136911A (ja) * 2009-12-25 2011-07-14 Tosoh Corp 甲状腺刺激ホルモンレセプターの安定化方法
WO2014052461A1 (en) * 2012-09-25 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment of central nervous system (cns) injury
WO2018200290A1 (en) * 2017-04-24 2018-11-01 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase abc
US9796970B1 (en) 2017-04-24 2017-10-24 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase ABC

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757964A (en) 1986-07-17 1988-07-19 Hughes Aircraft Company Method for controlling the attitude of a spinning body in orbit
US5270194A (en) * 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
WO1991006303A1 (en) 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
AU697156B2 (en) 1993-04-23 1998-10-01 American Cyanamid Company Cloning and expression of the chondroitinase I and II genes from (p. vulgaris)
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
AU1176595A (en) 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
DE69528128T2 (de) 1994-06-10 2003-03-13 United States Surgical Corp., Norwalk Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5792743A (en) 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
JP3702450B2 (ja) * 1996-12-18 2005-10-05 ニプロ株式会社 乳酸脱水素酵素測定用試薬
US6200564B1 (en) 1997-04-11 2001-03-13 J. Thomas Lamont Pharmaceutical compositions containing chondroitinase and uses therefor
JP4172842B2 (ja) * 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
DE69829605T2 (de) * 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
AU735216B2 (en) 1997-08-22 2001-07-05 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
US6153187A (en) 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
US20010006630A1 (en) 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
IL135345A0 (en) 1997-10-17 2001-05-20 Genentech Inc Human toll homologues
WO1999040787A1 (en) 1998-02-13 1999-08-19 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
KR20010034576A (ko) 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
WO1999046368A2 (en) 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6171575B1 (en) 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
CA2341412A1 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
MXPA01003538A (es) 1998-10-06 2005-09-08 Rush Presbyterian St Luke Metodo para el tratamiento de quimionucleolisis.
CA2364690A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
CA2365040A1 (en) 1999-04-02 2000-10-12 Eli Lilly And Company Hob-bp2h compositions, methods and uses thereof
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
PT1544299E (pt) 1999-06-08 2009-03-18 Regeneron Pharma Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular
EP1263459A2 (en) 1999-12-02 2002-12-11 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
MXPA02012743A (es) 2000-06-22 2003-04-25 Amgen Inc Moleculas tipo il-17 y usos de las mismas.
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP2319936A3 (en) 2001-02-15 2012-10-17 The University of Chicago Yeast screens for agents affecting protein folding
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
AU2002311535A1 (en) 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
US20030077258A1 (en) 2001-08-13 2003-04-24 Muir David F. Materials and methods for nerve grafting
US20030049258A1 (en) 2001-09-11 2003-03-13 Martin Ungerer Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
JP2005505285A (ja) 2001-10-09 2005-02-24 イミュネックス・コーポレーション 哺乳動物ｃ型レクチン
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
WO2003100031A2 (en) 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
ATE481478T1 (de) 2002-06-03 2010-10-15 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US7163545B2 (en) 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
US7074581B2 (en) 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
JP4527950B2 (ja) * 2002-08-09 2010-08-18 シスメックス株式会社 脂質測定試薬
KR20050062525A (ko) 2002-08-10 2005-06-23 예일 유니버시티 Ｎｏｇｏ 수용체 길항제
EP1530643B1 (en) 2002-08-15 2011-05-04 Acorda Therapeutics, Inc. Chimeric protein
JP2004113166A (ja) * 2002-09-27 2004-04-15 Mitsui Chemicals Inc ハロペルオキシダ−ゼ活性の安定化方法
ES2636653T3 (es) 2003-05-16 2017-10-06 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US20080025963A1 (en) 2003-05-16 2008-01-31 Gruskin Elliott A Compositions and methods for the treatment of CNS injuries
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
WO2004110359A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
US7507570B2 (en) 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Also Published As

Publication number Publication date
US8226941B2 (en) 2012-07-24
EP1750757A2 (en) 2007-02-14
AU2005244933A1 (en) 2005-12-01
JP4926962B2 (ja) 2012-05-09
CA2566731A1 (en) 2005-12-01
ES2411504T3 (es) 2013-07-05
WO2005112986A3 (en) 2009-04-16
AU2005244933B2 (en) 2011-08-04
EP1750757B1 (en) 2013-03-13
CA2566731C (en) 2012-07-24
EP1750757A4 (en) 2010-01-13
JP2008505661A (ja) 2008-02-28
US20080311642A1 (en) 2008-12-18
WO2005112986A2 (en) 2005-12-01
MXPA06013345A (es) 2008-10-31

Similar Documents

Publication Publication Date Title
MX341243B (es) Formulacion que comprende una enzima de degradacion de proteoglicano.
MX2009007632A (es) Precipitacion de polielectrolito y purificacion de proteinas.
NO20071811L (no) Rotasjonsseparator, samt fremgangsmate
NO20065290L (no) Fremgangsmate for a rense plasmid-DNA
MX2009000026A (es) Metodo para la purificacion del virus de influenza.
WO2007133596A3 (en) Method and system for production of zein and/or xanthophylls using chromatography
MX2007004696A (es) Metodos de purificacion viral mejorados.
WO2002083710A3 (en) Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
IL150892A0 (en) Process for producing peptides by using in vitro transcription/translation system
CA2216979A1 (en) Process for extracting and purifying lignans and cinnamic acid derivatives from flaxseed
DE59912722D1 (de) Kontinuierliches verfahren zur trennung von stoffen nach molekülgrösse
MX2009005012A (es) Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
WO2014005014A3 (en) Purification of iduronate-2-sulfatase
HK1138290A1 (en) Method of purification of hydrophobic proteins
WO2003039702A3 (en) Methods and compositions for chromatography
BRPI0413907A (pt) método de preparação de plasmìdeo dna de grau farmacêutico
CN109503705B (zh) 一种利拉鲁肽的分离纯化方法
NO20015703D0 (no) Fremgangsmåter for DNA rensing og renset DNA
DK1960521T3 (da) Fremgangsmåde og test kit til separation, oprensning og genvinding af lang- og kortkædede nukleinsyrer
WO2006127973A3 (en) Methods for separating and analyzing anionic compounds
BR9810650A (pt) Vetor para expressão de proteìna heteróloga e métodos para extrair proteìna recombinante e para purificar insulina recombinante isolada
EP1689853A4 (en) SEPARATION OF SPERM CELLS BY ELECTROPHORESIS
WO2022072836A3 (en) Methods for purification of messenger rna
EP0816374A3 (en) A method of preparing a composition containing a high proportion of ganglioside
UA86986C2 (ru) Композиция очищенного арабиногалактан-протеина (agp)